The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease
Background and purpose: Diabetes mellitus (DM) is a major risk factor for coronary heart disease (CHD). Previous research has reported that the Fufang-Zhenzhu-Tiaozhi (FTZ) formula has obvious effects on the treatment of dyslipidemia and hyperglycemia. In the present study, we intended to establish...
Main Authors: | , , , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021-05-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332221001281 |
id |
doaj-0ae1afd6520c4d5fbe64af1ec8c7a3b2 |
---|---|
record_format |
Article |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Lixia Song Dongxing Zhang Caijuan Guo Zhanhui Gu Lexun Wang Yu Si Yao Hong Wang Zhihuan Zeng Weixuan Wang Yiqi Yang Weijian Bei Xianglu Rong Jiao Guo |
spellingShingle |
Lixia Song Dongxing Zhang Caijuan Guo Zhanhui Gu Lexun Wang Yu Si Yao Hong Wang Zhihuan Zeng Weixuan Wang Yiqi Yang Weijian Bei Xianglu Rong Jiao Guo The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease Biomedicine & Pharmacotherapy Fufang-Zhenzhu-Tiaozhi (FTZ) Myocardial injury Diabetes mellitus (DM) Coronary heart disease (CHD) Inflammation |
author_facet |
Lixia Song Dongxing Zhang Caijuan Guo Zhanhui Gu Lexun Wang Yu Si Yao Hong Wang Zhihuan Zeng Weixuan Wang Yiqi Yang Weijian Bei Xianglu Rong Jiao Guo |
author_sort |
Lixia Song |
title |
The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease |
title_short |
The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease |
title_full |
The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease |
title_fullStr |
The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease |
title_full_unstemmed |
The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease |
title_sort |
traditional chinese medicine formula fufang-zhenzhu-tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart disease |
publisher |
Elsevier |
series |
Biomedicine & Pharmacotherapy |
issn |
0753-3322 |
publishDate |
2021-05-01 |
description |
Background and purpose: Diabetes mellitus (DM) is a major risk factor for coronary heart disease (CHD). Previous research has reported that the Fufang-Zhenzhu-Tiaozhi (FTZ) formula has obvious effects on the treatment of dyslipidemia and hyperglycemia. In the present study, we intended to establish a convenient DM-CHD model in minipigs and investigated the protective effect of FTZ against myocardial injury and its mechanism. Methods: The DM-CHD model was established by a high-fat/high-sucrose/high-cholesterol diet (HFSCD) combined with balloon injury in the coronary artery. Subsequently, sixteen Wuzhishan minipigs were assigned to three groups: control group, model group, and FTZ group. The model group and FTZ group were given a HFSCD, while the control group was given a normal diet (ND). FTZ was given with meals in the FTZ group. During this time, biochemical parameters, such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG), were measured by using testing kits. Insulin (INS) was determined by ELISA, and the homeostasis model assessment index of insulin resistance (HOMA-IR) was calculated to evaluate insulin resistance levels. After FTZ administration, the plasma levels of lactate dehydrogenase (LDH), creatine kinase isoenzyme MB (CK-MB), and cardiac troponin I (cTnI) were measured by using ELISA kits to evaluate myocardial injury. Coronary artery stenosis was analyzed by angiographic and HE staining. Myocardial ischemia was assayed with electrocardiogram (ECG). Moreover, cytokines, including interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), and tumor necrosis factor-alpha (TNF-α), were measured by ELISA kits to assess inflammation. The myocardial tissue was collected, and the pathological morphology was observed by transmission electron microscopy (TEM), HE staining, and Masson staining. Western blots were used to detect the expression of PI3K, AKT, p-AKT, p-NF-κB, and NF-κB. Results: A DM-CHD model in minipigs with glucose-lipid metabolism disorder, coronary artery incrassation and myocardial damage was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ effectively inhibited coronary artery incrassation and protected the myocardium against injury in DM-CHD minipigs. FTZ decreased proinflammatory cytokine levels and upregulated the protein expression of the PI3K/Akt pathway in the myocardium. Conclusions: A novel DM-CHD model in minipigs was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ has a protective effect against myocardial injury in DM-CHD by inhibiting inflammation and activating the PI3K/AKT signaling pathway. |
topic |
Fufang-Zhenzhu-Tiaozhi (FTZ) Myocardial injury Diabetes mellitus (DM) Coronary heart disease (CHD) Inflammation |
url |
http://www.sciencedirect.com/science/article/pii/S0753332221001281 |
work_keys_str_mv |
AT lixiasong thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT dongxingzhang thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT caijuanguo thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT zhanhuigu thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT lexunwang thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT yusiyao thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT hongwang thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT zhihuanzeng thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT weixuanwang thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT yiqiyang thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT weijianbei thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT xianglurong thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT jiaoguo thetraditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT lixiasong traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT dongxingzhang traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT caijuanguo traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT zhanhuigu traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT lexunwang traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT yusiyao traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT hongwang traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT zhihuanzeng traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT weixuanwang traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT yiqiyang traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT weijianbei traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT xianglurong traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease AT jiaoguo traditionalchinesemedicineformulafufangzhenzhutiaozhiprotectsmyocardiafrominjuryindiabeticminipigswithcoronaryheartdisease |
_version_ |
1721301958197772288 |
spelling |
doaj-0ae1afd6520c4d5fbe64af1ec8c7a3b22021-07-15T04:26:42ZengElsevierBiomedicine & Pharmacotherapy0753-33222021-05-01137111343The traditional Chinese medicine formula Fufang-Zhenzhu-Tiaozhi protects myocardia from injury in diabetic minipigs with coronary heart diseaseLixia Song0Dongxing Zhang1Caijuan Guo2Zhanhui Gu3Lexun Wang4Yu Si Yao5Hong Wang6Zhihuan Zeng7Weixuan Wang8Yiqi Yang9Weijian Bei10Xianglu Rong11Jiao Guo12Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, China; Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaDepartment of Cardiovascular Diseases, the First Affiliated Hospital of Guangdong Pharmaceutical University, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, China; Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, China; Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, China; Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, China; Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, ChinaGuangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, China; Key Laboratory of Glucolipid Metabolic Disorder, Ministry of Education of China, China; Key Unit of Modulating Liver to Treat Hyperlipemia SATCM (State Administration of Traditional Chinese Medicine), China; Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangdong TCM Key Laboratory against Metabolic Diseases, China; Correspondence to: Guangdong Metabolic Disease Research Center of Integrated Chinese and Western Medicine, The Institute of Chinese Medicinal Sciences, Guangdong Pharmaceutical University, Guangzhou 510006, China.Background and purpose: Diabetes mellitus (DM) is a major risk factor for coronary heart disease (CHD). Previous research has reported that the Fufang-Zhenzhu-Tiaozhi (FTZ) formula has obvious effects on the treatment of dyslipidemia and hyperglycemia. In the present study, we intended to establish a convenient DM-CHD model in minipigs and investigated the protective effect of FTZ against myocardial injury and its mechanism. Methods: The DM-CHD model was established by a high-fat/high-sucrose/high-cholesterol diet (HFSCD) combined with balloon injury in the coronary artery. Subsequently, sixteen Wuzhishan minipigs were assigned to three groups: control group, model group, and FTZ group. The model group and FTZ group were given a HFSCD, while the control group was given a normal diet (ND). FTZ was given with meals in the FTZ group. During this time, biochemical parameters, such as total cholesterol (TC), triglyceride (TG), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein (HDL-C), and fasting blood glucose (FBG), were measured by using testing kits. Insulin (INS) was determined by ELISA, and the homeostasis model assessment index of insulin resistance (HOMA-IR) was calculated to evaluate insulin resistance levels. After FTZ administration, the plasma levels of lactate dehydrogenase (LDH), creatine kinase isoenzyme MB (CK-MB), and cardiac troponin I (cTnI) were measured by using ELISA kits to evaluate myocardial injury. Coronary artery stenosis was analyzed by angiographic and HE staining. Myocardial ischemia was assayed with electrocardiogram (ECG). Moreover, cytokines, including interleukin-6 (IL-6), hypersensitive C-reactive protein (hs-CRP), and tumor necrosis factor-alpha (TNF-α), were measured by ELISA kits to assess inflammation. The myocardial tissue was collected, and the pathological morphology was observed by transmission electron microscopy (TEM), HE staining, and Masson staining. Western blots were used to detect the expression of PI3K, AKT, p-AKT, p-NF-κB, and NF-κB. Results: A DM-CHD model in minipigs with glucose-lipid metabolism disorder, coronary artery incrassation and myocardial damage was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ effectively inhibited coronary artery incrassation and protected the myocardium against injury in DM-CHD minipigs. FTZ decreased proinflammatory cytokine levels and upregulated the protein expression of the PI3K/Akt pathway in the myocardium. Conclusions: A novel DM-CHD model in minipigs was successfully established through balloon injury in the coronary artery combined with HFSCD. FTZ has a protective effect against myocardial injury in DM-CHD by inhibiting inflammation and activating the PI3K/AKT signaling pathway.http://www.sciencedirect.com/science/article/pii/S0753332221001281Fufang-Zhenzhu-Tiaozhi (FTZ)Myocardial injuryDiabetes mellitus (DM)Coronary heart disease (CHD)Inflammation |